SCHEMBL509733

SCHEMBL509733

ClCc1cc(Cl)ccn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29774155 1.00
Hydrochloric Acid SCHEMBL31198157 0.98 PDE8A (0.39)
Hydrochloric Acid SCHEMBL1157373 0.98 PDE8A (0.39)
SCHEMBL5955760 0.79
SCHEMBL17103357 0.79
SCHEMBL5017729 0.79
SCHEMBL510676 0.79
SCHEMBL3196761 0.79
SCHEMBL7668989 0.79
SCHEMBL1507045 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121698848-B Iron complex with triazacyclononane macrocyclic skeleton, and preparation method and application thereof Quzhou Research Institute of Zhejiang University (CN) 2026-05-26 CN disclosed
US-20250179061-A1 RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2025-06-05 US disclosed
US-20250134907-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-05-01 US disclosed
US-20240400471-A1 LABELING METHOD, OXIDANT FOR LABELING, RUTHENIUM COMPLEX, CATALYST, LABELING COMPOUND, AND COMPOUND KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2024-12-05 US disclosed
US-20240368133-A1 Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling CONFO THERAPEUTICS N.V. (BE) 2024-11-07 US disclosed
US-20240327408-A1 COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF CHINA PHARMACEUTICAL UNIVERSITY (CN) 2024-10-03 US disclosed
WO-2024131938-A1 QUINAZOLINE COMPOUND AND USE THEREOF 赛诺哈勃药业(成都)有限公司 2024-06-27 WO disclosed
CN-118159530-A Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling 康福治疗有限公司 2024-06-07 CN disclosed
EP-4377307-A1 COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING Confo Therapeutics N.V. (BE) 2024-06-05 EP disclosed
WO-2024034666-A1 RUTHENIUM COMPLEX, METHOD FOR PRODUCING SAME, CATALYST COMPOSITION, OXIDATION METHOD AND METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND 国立大学法人九州大学 2024-02-15 WO disclosed
EP-0684949-A4 CHEMICAL COMPOUNDS. SMITHKLINE BEECHAM CORP (US) 1995-10-13 EP disclosed
WO-1995018122-A2 HETEROARYLPYRROLES CIBA-GEIGY AG (CH) 1995-07-06 WO disclosed
WO-1995013267-A1 PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS THE UPJOHN COMPANY (US) 1995-05-18 WO disclosed
WO-1994019354-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1994-09-01 WO disclosed
US-4855420-A Cephalosporin derivatives ICI PHARMA (FR) 1989-08-08 US disclosed
EP-0256990-A1 Pyridinio compounds CIBA-GEIGY AG (CH) 1988-02-24 EP disclosed
US-4678781-A BACTERICIDAL ANTIBIOTICS ICI PHARMA (FR) 1987-07-07 US disclosed
US-4266964-A SAID ANTIDOTES BEING CHLOROPYRIDINE COMPOUNDS THE DOW CHEMICAL COMPANY (US) 1981-05-12 US disclosed
US-3992388-A INTERMEDIATE FOR SULFAMYLUREA HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1976-11-16 US disclosed
US-3933830-A FROM 4-(2-PYRIDYLAMIDOETHYL) PYRIDINES REDUCED WITH HYDROGEN AND A NOBLE METAL CATALYST PFIZER INC. (US) 1976-01-20 US disclosed